The 2019 Report on Adherence to and Compliance with Arms Control, Nonproliferation, and Disarmament Agreements and Commitments argued that there were "serious questions regarding whether Iran intended to preserve the option to resume elements of a nuclear weapons program in the future in the event a decision were made to do so". It also assessed that "nowhere is the current challenge posed by missile proliferation and the expansion of missile capabilities more clear than in the case of Iran", and additionally posited that Iran was "pursuing pharmaceutical-based agents for offensive purposes".